slides · global inventory
All filtered slides
Global slide inventory for the active corpus filters, with each row opening the slide detail view.
Corpus coverage
319,975 slides
319,974 are described (100%), so the treemap can explain the corpus instead of just counting files.
- Total slides
- 319,975
- Described
- 319,974
- Pending
- 1
100%ready for canon
Slide type composition
dynamicclickable
Slide type
Showing 319,974 described slides — 100.0% of 319,975 rendered pages
+Context & problem43,76713.7% · 6,592 docs+Data & charts72,62022.7% · 8,666 docs+Meta & navigation45,93614.4% · 9,739 docs+Recommend & act67,04121.0% · 9,324 docs+Cases & evidence31,2569.8% · 6,067 docs+Frameworks2,1230.7% · 1,232 docs+Appendix35,68211.2% · 6,614 docs+Other21,5496.7% · 5,566 docs
Tile area is proportional to slide count. Click a category to open its subtype map.
all document kinds · all orientations
Slide collection
226,051-226,080 of 319,975
13
The slide highlights the structural advantage of the HSL configuration using a (GGGGS)5 linker.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Solution & Approach1 hit
14
The diagram highlights four key clinical outcomes: no Parkinson's-like symptoms, short hospital stays, broad hospital access, and no deaths in clinical trials.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Solution & Approach1 hit
15
The slide highlights a significant difference in neurotoxicity percentages (4% vs 23-28%) and CRS onset/duration metrics.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Solution & Approach1 hit
16
The slide uses a biological illustration to highlight structural differences in binding domains and intracellular signaling components.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Solution & Approach1 hit
17
Includes comparative data points for CAR-T characteristics.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Solution & Approach1 hit
18
The chart illustrates the pharmacokinetics of the NXC-201 (HBI0101) therapy, highlighting a 30-day clearance window.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Solution & Approach1 hit
19
The slide uses a process flow diagram to connect cellular pathology to clinical manifestations.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Evidence & Proof1 hit
20
The diagram shows a summation of ~29,712 (prevalence) and ~3,040 (derived from incidence) to reach ~32,752 eligible patients.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Evidence & Proof1 hit
21
The slide contrasts existing multi-drug combination therapies with the proposed monotherapy NXC-201.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Evidence & Proof1 hit
22
The slide uses a grouped bar chart to compare hematologic response and cardiac response (NT-proBNP reduction) across four treatment categories.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Evidence & Proof1 hit
23
The slide uses a visual timeline/chart hybrid to compare CAR-T cell expansion, sBCMA reduction, and side effect durations (CRS and ICANS) across three products.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Evidence & Proof1 hit
24
The slide uses a table structure to contrast treatment landscapes and patient outcomes, with a bar chart at the bottom illustrating patient growth.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Evidence & Proof1 hit
25
The slide uses a visual bridge to highlight a 67% improvement in response rates for NXC-201 compared to the average of the three competitors shown.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Evidence & Proof1 hit
26
Includes a footnote citing FDA approval precedents for similar single-arm studies.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Evidence & ProofLoop · Why Now1 hit
27
The slide uses a before-and-after visual comparison to illustrate market expansion.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Evidence & ProofLoop · Why Now1 hit
28
Includes detailed source citations in the footer.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Evidence & ProofLoop · Why Now1 hit
29
The slide uses a two-column layout to separate milestones for two distinct drug programs.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Evidence & ProofLoop · Why Now1 hit
30
The slide uses a standard pharmaceutical pipeline table format to communicate clinical progress and regulatory milestones.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Evidence & ProofLoop · Quick Win Big Bet1 hit
31
Includes a comparative table of clinical outcomes (ORR/CR/sCR) for NXC-201 vs. competitors.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Evidence & ProofLoop · Quick Win Big Bet1 hit
32
The slide uses a wave-like visual to represent market segments and their associated dollar values.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Evidence & ProofLoop · Quick Win Big Bet1 hit
33
The table highlights superior response rates (100% ORR, 70% CR) for NXC-201 compared to competitors.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Evidence & Proof1 hit
34
The table uses a red dashed box to highlight key clinical efficacy and safety metrics (ORR, CR, ICANS, CRS).Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Evidence & Proof1 hit
35
The chart compares NXC-201 against other therapies categorized by prior BCMA treatment status.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Evidence & Proof1 hit
36
The slide uses a two-column layout to contrast clinical outcomes for two different indications, followed by a row of competitor product logos and financial metrics.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Evidence & Proof1 hit
37
The chart illustrates deepening responses in patients treated with NXC-201 over time.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Impact & Next Steps1 hit
38
The slide uses a combination of biological pathway diagrams, pharmacokinetic data, and efficacy metrics to demonstrate the therapeutic advantage of IMX-110.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Impact & Next Steps1 hit
39
The slide uses a numbered list format to present clinical milestones and market opportunities.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Impact & Next Steps1 hit
40
Immix Biopharma | Investor Presentation Deck | 64 slidesImmix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Impact & Next Steps1 hit
41
Uses icon-based visualization to represent market expansion.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Impact & Next Steps1 hit
42
The slide uses a process flow diagram to illustrate dose escalation steps.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Impact & Next Steps1 hit